Frontiers in oncology · 2026
Long-term control for > 9 years with megestrol acetate-letrozole: metastatic endometrioid carcinoma case report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Lixia, Ma Lina, Yang Lu, He Wenguang
Аннотация
BACKGROUND: Hormone receptor-positive (HR+) endometrial carcinoma (EC) responds to endocrine therapy, but clinical benefit duration is often limited, especially in patients with widely metastatic or recurrent disease.
CASE: A 54-year-old woman with HR-high (ER/PR 90%) metastatic EC (FIGO IIIC2) discontinued adjuvant chemotherapy due to severe toxicity. She initiated megestrol acetate and letrozole in March 2017, achieving stable disease (SD) for 38 months. Self-discontinuation (January-July 2020) led to disease progression (new retroperitoneal lymph nodes), but resuming full-dose therapy restored SD for 49 months. After dose reduction (July 2023), the disease progressed again at 12 months; re-escalation to full dose induced regression. At last follow-up (OS: 108 months), she maintained SD with minimal toxicity.
CONCLUSION: This is the first case demonstrating that full-dose megestrol acetate plus letrozole may induce durable antitumor activity in HR-high expression metastatic EC, warranting prospective validation.
CASE: A 54-year-old woman with HR-high (ER/PR 90%) metastatic EC (FIGO IIIC2) discontinued adjuvant chemotherapy due to severe toxicity. She initiated megestrol acetate and letrozole in March 2017, achieving stable disease (SD) for 38 months. Self-discontinuation (January-July 2020) led to disease progression (new retroperitoneal lymph nodes), but resuming full-dose therapy restored SD for 49 months. After dose reduction (July 2023), the disease progressed again at 12 months; re-escalation to full dose induced regression. At last follow-up (OS: 108 months), she maintained SD with minimal toxicity.
CONCLUSION: This is the first case demonstrating that full-dose megestrol acetate plus letrozole may induce durable antitumor activity in HR-high expression metastatic EC, warranting prospective validation.